B+
Bull case
0%
Probability
Target price
$225.00
+16.2% vs current
DGX
Quest DiagnosticsCNYSE / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$205.00
+5.9% vs current
B-
Bear case
0%
Probability
Target price
$182.00
-6.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-21
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+52.4
Score
AI commentary
Quest's latest primary-source update is constructive, but the setup still looks like a solid execution story in a well-followed name rather than a fresh underappreciated inflection. The direct peer set available here is thin outside Labcorp, which limits how aggressive the relative-call framing should be. With a neutral deterministic prior, moderate evidence quality, and limited truly new forward hooks beyond the guide raise, the most defensible read remains cautious positive-to-neutral monitoring.
RankAlpha Sentiment Codex - 2026-04-21
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-05-31catalystQ1 beat and FY26 guide raise create a near-term reset windowMedium impact
Quest reported Q1 2026 revenue of $2.895 billion, up 9.2%, with 10.9% requisition volume growth and adjusted EPS of $2.50, then raised full-year 2026 guidance to $11.78-$11.90 billion of revenue and $10.63-$10.83 of adjusted EPS; that supports a near-term estimate-reset tailwind, although much of the good news was disclosed immediately with the filing [#8-K-2026-04-21].
2026-07-21eventNext quarterly checkpoint must validate that volume-led growth is durableMedium impact
The next earnings checkpoint, likely around late July 2026 based on Quest's quarterly reporting cadence (inference), is important because Q1 growth was driven by strong volume while revenue per requisition was down 1.3%; after the guidance raise, investors will likely want confirmation that volume, mix, and margin remain supportive rather than treating Q1 as a one-off beat [#8-K-2026-04-21].
2026-11-15catalystAdvanced diagnostics, consumer channel, and system partnerships provide longer-duration upside but remain execution-dependentMedium impact
Quest highlighted double-digit growth in several Advanced Diagnostics areas, robust consumer-channel growth, ongoing Corewell Health Co-Lab and joint-venture progress, and multi-year Project Nova work; these are real operating levers, but they look more like steady execution drivers than sharp near-term inflections, which argues for a monitoring stance rather than an aggressive rerating call [#8-K-2026-04-21].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-21 • Updated nightlySource: Internal modelMethodology